Anika Therapeutics Valuation
| ANIK Stock | USD 17.28 0.35 2.07% |
At this time, the firm appears to be fairly valued. Anika Therapeutics shows a prevailing Real Value of $16.66 per share. The current price of the firm is $17.28. Our model approximates the value of Anika Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.43, profit margin of (0.59) %, and Current Valuation of 213.12 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Anika Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Anika Therapeutics is based on 3 months time horizon. Increasing Anika Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Anika Therapeutics' intrinsic value may or may not be the same as its current market price of 17.28, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 17.28 | Real 16.66 | Hype 17.28 | Naive 17.55 |
The intrinsic value of Anika Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Anika Therapeutics' stock price.
Estimating the potential upside or downside of Anika Therapeutics helps investors to forecast how Anika stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Anika Therapeutics more accurately as focusing exclusively on Anika Therapeutics' fundamentals will not take into account other important factors: Anika Therapeutics Total Value Analysis
Anika Therapeutics is presently forecasted to have valuation of 213.12 M with market capitalization of 253.08 M, debt of 29.04 M, and cash on hands of 87.78 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Anika Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
213.12 M | 253.08 M | 29.04 M | 87.78 M |
Anika Therapeutics Investor Information
About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. Anika Therapeutics recorded a loss per share of 6.64. The entity had not issued any dividends in recent years. Based on the key indicators related to Anika Therapeutics' liquidity, profitability, solvency, and operating efficiency, Anika Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Anika Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Anika Therapeutics has an asset utilization ratio of 61.58 percent. This suggests that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that Anika Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Anika Therapeutics Ownership Allocation
The market capitalization of Anika Therapeutics is $253.08 Million. The majority of Anika Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Anika Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Anika Therapeutics. Please pay attention to any change in the institutional holdings of Anika Therapeutics as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Anika Therapeutics Profitability Analysis
The company reported the previous year's revenue of 166.66 M. Net Loss for the year was (82.67 M) with profit before overhead, payroll, taxes, and interest of 80.23 M.About Anika Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Anika Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Anika Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Anika Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Anika Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Anika Therapeutics. We calculate exposure to Anika Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Anika Therapeutics's related companies.Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 297 people.
Anika Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Anika Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 14.7 M | |
| Quarterly Earnings Growth Y O Y | -0.505 | |
| Forward Price Earnings | 35.9712 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.